Literature DB >> 24981001

Chondrosarcoma of the tibial head during pregnancy: a challenging diagnosis.

Philip P Roessler1, Jan Schmitt1, Susanne Fuchs-Winkelmann1, Turgay Efe1.   

Abstract

Chondrosarcoma is one of the most common malignant bone tumours in adults. However, it rarely occurs during pregnancy. Therefore, reports on surgical and medical management of this entity are hard to find. Different studies suggest a possible growth-enhancing effect of altered hormone levels on various bone tumours. The effect of pregnancy on growth characteristics of chondrosarcomas however remains unclear. We report a case of a 32-year-old pregnant woman with a newly occurred chondrosarcoma of the tibial head. Intense clinical monitoring and repeated MRI scans showed a tumour progression during pregnancy followed by the need of above-knee amputation after 30 weeks gestation. Spontaneous vaginal delivery after 38 weeks gestation was complicated by an amniotic infection syndrome and finally stopped, necessitating a caesarean section. Despite this there were no further complications to be mentioned. No local tumour recurrence or metastases could be detected in the staging CT scans following pregnancy. 2014 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Year:  2014        PMID: 24981001      PMCID: PMC4078444          DOI: 10.1136/bcr-2014-205210

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  14 in total

1.  Clinical outcome of central conventional chondrosarcoma.

Authors:  Andrea Angelini; Giovanni Guerra; Andreas F Mavrogenis; Elisa Pala; Piero Picci; Pietro Ruggieri
Journal:  J Surg Oncol       Date:  2012-05-30       Impact factor: 3.454

2.  Prognostic factors in chondrosarcoma of bone: a clinicopathologic analysis with emphasis on histologic grading.

Authors:  H L Evans; A G Ayala; M M Romsdahl
Journal:  Cancer       Date:  1977-08       Impact factor: 6.860

3.  The inguinal paravascular technic of lumbar plexus anesthesia: the "3-in-1 block".

Authors:  A P Winnie; S Ramamurthy; Z Durrani
Journal:  Anesth Analg       Date:  1973 Nov-Dec       Impact factor: 5.108

4.  Chondrosarcoma in the left hemipelvis imitating a pelvic ovarian mass in pregnancy: a case report.

Authors:  G Somoye; S Havenga
Journal:  Clin Exp Obstet Gynecol       Date:  2010       Impact factor: 0.146

5.  Nonobstetrical abdominal surgery during pregnancy in Women's Hospital.

Authors:  T S Gerstenfeld; D T Chang; A R Pliego; D A Wing
Journal:  J Matern Fetal Med       Date:  2000 May-Jun

6.  Extraskeletal myxoid chondrosarcoma of the cerebellopontine angle presenting during pregnancy.

Authors:  J O'Brien; J Thornton; D Cawley; M Farrell; K Keohane; G Kaar; L McEvoy; D F O'Brien
Journal:  Br J Neurosurg       Date:  2008-06       Impact factor: 1.596

7.  Grade I chondrosarcoma of bone: the Münster experience.

Authors:  Arne Streitbürger; Helmut Ahrens; Maurice Balke; Horst Buerger; Winfried Winkelmann; Georg Gosheger; Jendrik Hardes
Journal:  J Cancer Res Clin Oncol       Date:  2008-10-15       Impact factor: 4.553

8.  Immunohistochemical expression of estrogen receptors in chondrosarcomas and enchondromas.

Authors:  Thomas J Grifone; Helen M Haupt; Victoria Podolski; John J Brooks
Journal:  Int J Surg Pathol       Date:  2008-01       Impact factor: 1.271

9.  A system of staging musculoskeletal neoplasms.

Authors:  W F Enneking
Journal:  Clin Orthop Relat Res       Date:  1986-03       Impact factor: 4.176

10.  Bone cancers.

Authors:  H D Dorfman; B Czerniak
Journal:  Cancer       Date:  1995-01-01       Impact factor: 6.860

View more
  2 in total

1.  Internal hemipelvectomy is a safe procedure and provides a satisfying outcome for pelvic chondrosarcoma with coexisting pregnancy.

Authors:  I Gede Eka Wiratnaya
Journal:  J Clin Orthop Trauma       Date:  2019-06-01

Review 2.  Bone and soft tissue sarcomas during pregnancy: A narrative review of the literature.

Authors:  George Zarkavelis; Dimitrios Petrakis; George Fotopoulos; Sotirios Mitrou; Nicholas Pavlidis
Journal:  J Adv Res       Date:  2016-02-02       Impact factor: 10.479

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.